Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002736 (
amyotrophic lateral sclerosis
)
19,048
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Senataxin is a large 303 kDa protein linked to neuron survival, as recessive mutations cause Ataxia with Oculomotor Apraxia type 2 (AOA2), and dominant mutations cause
amyotrophic lateral sclerosis
type 4 (ALS4). Senataxin contains an amino-terminal protein-interaction domain and a carboxy-terminal DNA/RNA helicase domain. In this study, we focused upon the common ALS4 mutation, L389S, by performing yeast two-hybrid screens of a human brain expression library with control
senataxin
or L389S
senataxin
as bait. Interacting clones identified from the two screens were collated, and redundant hits and false positives subtracted to yield a set of 13 protein interactors. Among these hits, we discovered a highly specific and reproducible interaction of L389S
senataxin
with a peptide encoded by the antisense sequence of a brain-specific non-coding RNA, known as BCYRN1. We further found that L389S
senataxin
interacts with other proteins containing regions of conserved homology with the BCYRN1 reverse complement-encoded peptide, suggesting that such aberrant protein interactions may contribute to L389S ALS4 disease pathogenesis. As the yeast two-hybrid screen also demonstrated
senataxin
self-association, we confirmed
senataxin
dimerization via its amino-terminal binding domain and determined that the L389S mutation does not abrogate
senataxin
self-association. Finally, based upon detection of interactions between
senataxin
and ubiquitin-SUMO pathway modification enzymes, we examined
senataxin
for the presence of ubiquitin and SUMO monomers, and observed this post-translational modification. Our
senataxin
protein interaction study reveals a number of features of
senataxin
biology that shed light on
senataxin
normal function and likely on
senataxin
molecular pathology in ALS4.
...
PMID:Protein interaction analysis of senataxin and the ALS4 L389S mutant yields insights into senataxin post-translational modification and uncovers mutant-specific binding with a brain cytoplasmic RNA-encoded peptide. 2424 71
Development of Alzheimer's disease (AD) is characterized by progressive neuronal death and a decline in learning and memory. Mutations in human
senataxin
(
SETX
), an ortholog yeast protein of Sen1, have been identified to cause the syndrome of ataxia with oculomotor apraxia type 2 (AOA2) and juvenile
amyotrophic lateral sclerosis
(ALS4), two types of progressive motor neuron degeneration. However, the relationship between the
SETX
gene, which is involved in the regulation of RNA processing and DNA repair, and the predisposition for AD remains unclear. In this research, potential association of polymorphisms in the
SETX
gene with AD was investigated. A case-control study of a Chinese Han population in Taiwan was performed. Three single-nucleotide polymorphisms (SNPs), 3455T>G (rs3739922), 3576T>G (rs1185193) and 7759A>G (rs1056899) were studied. The experimental data showed that upon genotyping of the exonic polymorphism in the
SETX
gene, the T allele appeared at a lower rate than the G allele at position 3455 in AD patients compared with normal groups (P < 0.05, odds ratio (OR), 0.59, 95% confidence interval (CI), 0.40-0.89). Subjects with the GA genotype at position 7759 have higher incidences of AD development than with the AA genotype (P < 0.05, OR, 6.45, 95% CI, 1.24 to 33.70). Our results also showed that with six haplotypes (Hts) observed from the analyzed polymorphisms, distributions of the Ht4-GAA and Ht5-GCA haplotypes appeared to be significant 'risk' haplotypes between AD patients and controls (both P < 0.05, OR, 8.44, 95% CI, 1.07-66.60). These observations suggest that genetic variations in the
SETX
gene may contribute to AD pathogenesis in the Taiwanese Han population.
...
PMID:Association of genetic variants in senataxin and Alzheimer's disease in a Chinese Han population in Taiwan. 2469 97
Senataxin, encoded by the SETX gene, contributes to multiple aspects of gene expression, including transcription and RNA processing. Mutations in SETX cause the recessive disorder ataxia with oculomotor apraxia type 2 (AOA2) and a dominant juvenile form of
amyotrophic lateral sclerosis
(ALS4). To assess the functional role of
senataxin
in disease, we examined differential gene expression in AOA2 patient fibroblasts, identifying a core set of genes showing altered expression by microarray and RNA-sequencing. To determine whether AOA2 and ALS4 mutations differentially affect gene expression, we overexpressed disease-specific SETX mutations in
senataxin
-haploinsufficient fibroblasts and observed changes in distinct sets of genes. This implicates mutation-specific alterations of
senataxin
function in disease pathogenesis and provides a novel example of allelic neurogenetic disorders with differing gene expression profiles. Weighted gene co-expression network analysis (WGCNA) demonstrated these
senataxin
-associated genes to be involved in both mutation-specific and shared functional gene networks. To assess this in vivo, we performed gene expression analysis on peripheral blood from members of 12 different AOA2 families and identified an AOA2-specific transcriptional signature. WGCNA identified two gene modules highly enriched for this transcriptional signature in the peripheral blood of all AOA2 patients studied. These modules were disease-specific and preserved in patient fibroblasts and in the cerebellum of Setx knockout mice demonstrating conservation across species and cell types, including neurons. These results identify novel genes and cellular pathways related to
senataxin
function in normal and disease states, and implicate alterations in gene expression as underlying the phenotypic differences between AOA2 and ALS4.
...
PMID:Mutation of senataxin alters disease-specific transcriptional networks in patients with ataxia with oculomotor apraxia type 2. 2476 Jul 70
Interest in
senataxin
biology began in 2004 when mutations were first identified in what was then a novel protein. Dominantly inherited mutations were documented in rare juvenile-onset, motor neuron disease pedigrees in a familial form of
amyotrophic lateral sclerosis
(ALS4), while recessive mutations were found to cause a severe early-onset ataxia with oculomotor apraxia (AOA2) that is actually the second most common recessive ataxia after Freidreich's ataxia. From earlier studies of sen1p, the yeast ortholog of
senataxin
, a range of important RNA processing functions have been attributed to this protein. Like sen1p,
senataxin
contains a helicase domain to interact with RNA and an amino-terminal domain for critical protein interactions. Senataxin also joins a group of important proteins responsible for maintaining RNA transcriptome homeostasis, including FUS, TDP-43, and SMN that can all cause familial forms of motor neuron disease (MND). Independent of this association,
senataxin
is gaining attention for its role in maintaining genomic stability. Senataxin has been shown to resolve R-Loop structures, which form when nascent RNA hybridizes to DNA, displacing the non-transcribed strand. But in cycling cells,
senataxin
is also found at nuclear foci during the S/G2 cell-cycle phase, and may function at sites of specific collision between components of the replisome and transcription machinery. Which of these important processes is most critical to prevent neurodegeneration remains unknown, but our evolving understanding of these processes will be crucial not only for understanding
senataxin
's role in neurological disease, but also in a number of fundamentally important cellular functions.
...
PMID:Unwinding the role of senataxin in neurodegeneration. 2572 27
The human helicase
senataxin
(
SETX
) has been linked to the neurodegenerative diseases
amyotrophic lateral sclerosis
(ALS4) and ataxia with oculomotor apraxia (AOA2). Here we identified a role for
SETX
in controlling the antiviral response. Cells that had undergone depletion of
SETX
and
SETX
-deficient cells derived from patients with AOA2 had higher expression of antiviral mediators in response to infection than did wild-type cells. Mechanistically, we propose a model whereby
SETX
attenuates the activity of RNA polymerase II (RNAPII) at genes stimulated after a virus is sensed and thus controls the magnitude of the host response to pathogens and the biogenesis of various RNA viruses (e.g., influenza A virus and West Nile virus). Our data indicate a potentially causal link among inborn errors in
SETX
, susceptibility to infection and the development of neurologic disorders.
...
PMID:Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis. 2582 50
Juvenile onset
amyotrophic lateral sclerosis
(
ALS
) is a very rare form of motor neuron disease, with the first symptoms of motor neuron degeneration manifested before 25 years of age. Juvenile
ALS
is more frequently familial in nature than the adult-onset forms. Mutations in the alsin (ALS2),
senataxin
(
SETX
), and Spatacsin (SPG11) have been associated with familial
ALS
with juvenile onset and slowly progression. Here we reported two apparently sporadic
ALS
with juvenile onset and aggressive progression caused by mutations in the SOD1 and FUS gene. We also reviewed juvenile-onset
ALS
in publications. Our findings, together with other researches, confirms that both SOD1 and FUS mutations can lead to juvenile-onset malignant form of
ALS
and should be screened in
ALS
patients with an earlier age of onset, aggressive progression, even if there is no apparent family history.
...
PMID:Mutations in SOD1 and FUS caused juvenile-onset sporadic amyotrophic lateral sclerosis with aggressive progression. 2648 17
The carboxy-terminal domain (CTD) of the RNA polymerase II (RNAP II) subunit POLR2A is a platform for modifications specifying the recruitment of factors that regulate transcription, mRNA processing, and chromatin remodelling. Here we show that a CTD arginine residue (R1810 in human) that is conserved across vertebrates is symmetrically dimethylated (me2s). This R1810me2s modification requires protein arginine methyltransferase 5 (PRMT5) and recruits the Tudor domain of the survival of motor neuron (SMN, also known as GEMIN1) protein, which is mutated in spinal muscular atrophy. SMN interacts with
senataxin
, which is sometimes mutated in ataxia oculomotor apraxia type 2 and
amyotrophic lateral sclerosis
. Because POLR2A R1810me2s and SMN, like
senataxin
, are required for resolving RNA-DNA hybrids created by RNA polymerase II that form R-loops in transcription termination regions, we propose that R1810me2s, SMN, and
senataxin
are components of an R-loop resolution pathway. Defects in this pathway can influence transcription termination and may contribute to neurodegenerative disorders.
...
PMID:SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination. 2670 Aug 5
Juvenile onset
ALS
is a very rare form of motor neuron disease, with the first symptoms of motor neuron degeneration manifested before 25 years of age. Mutations in the alsin (ALS2),
senataxin
(
SETX
), and spatacsin (SPG11) genes have been associated with familial
ALS
with juvenile onset and slow progression, whereas the genetic architecture of sporadic juvenile
ALS
remains unclear. We screened mutations in C9orf72, SOD1, FUS, TARDBP, ANG, VCP and PFN1 in 16 juvenile sporadic
ALS
patients. Four cases (25%) carrying FUS mutations and one individual (6%) harbouring a SOD1 mutation were identified. All cases had an aggressive disease course. Our results suggest that FUS mutations are the most frequent genetic cause in early-onset sporadic
ALS
patients of Chinese origin. Genetic testing of FUS should be performed in early-onset
ALS
patients especially those with an aggressive disease course.
...
PMID:Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin. 2697 16
R-loops comprise an RNA/DNA hybrid and a displaced single-stranded DNA. They play crucial biological functions and are implicated in neurological diseases, including ataxias,
amyotrophic lateral sclerosis
, nucleotide expansion disorders (Friedreich ataxia and fragile X syndrome), and cancer. Currently, it is unclear which mechanisms cause R-loop structures to become pathogenic. The RNA/DNA helicase
senataxin
(
SETX
) is one of the best characterised R-loop-binding factors in vivo. Mutations in
SETX
are linked to two neurodegenerative disorders: ataxia with oculomotor apraxia type 2 (AOA2) and
amyotrophic lateral sclerosis
type 4 (ALS4).
SETX
is known to play a role in transcription, neurogenesis, and antiviral response. Here, we review the causes of R-loop dysregulation in neurodegenerative diseases and how these structures contribute to pathomechanisms. We will discuss the importance of
SETX
as a genome guardian in suppressing aberrant R-loop formation and analyse how
SETX
mutations can lead to neurodegeneration in AOA2/ALS4. Finally, we will discuss the implications for other R-loop-associated neurodegenerative diseases and point to future therapeutic approaches to treat these disorders.
...
PMID:Senataxin: Genome Guardian at the Interface of Transcription and Neurodegeneration. 2777 83
We report a 44 years old man with slowly progressive muscular atrophy of the extremities for over 30 years. He experienced difficulty in walking in his 10's and was diagnosed as hereditary spastic paraplegia (HSP) in his 20's. And then, muscle atrophy of the extremities slowly progressed especially in his distal muscles. Sensory axonal neuropathy was detected with sural nerve biopsy. His father and uncle have been diagnosed as HSP in their early days. His father noticed weakness of his leg in his 20's. He lost motor function of the leg in his 60's. In addition, marked disturbance of thermal sensation, vibration, and sense of position were found by physical examination. Our genetic study detected
senataxin
(
SETX
) gene mutation (c.8C>T,p.T3I) in the blood of those two patients, and they had been identified as family cases of
amyotrophic lateral sclerosis
(
ALS
) 4. As clinical symptoms of ALS4 would be similar to those of HSP at the onset, we suggest considering ALS4 in seeing patients with HSP without gene diagnosis.
...
PMID:[A amyotrophic lateral sclerosis (ALS) 4 family misdiagnosed as hereditary spastic paraplegia-a case report]. 2907 Jul 49
<< Previous
1
2
3
Next >>